A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the ...

On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...

Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...

AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Explore AI in drug discovery and its journey from promise to proof in 2025 with significant achievements and challenges faced.

In a year from now, progress is to be measured in the institutionalisation of the approach with greater regulatory acceptance ...

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...